In an extensive interview with the Guardian, Bradley Wiggins has opened up properly for the first time about his controversial use of TUEs during his cycling career, his long standing allergies and asthma, his relationship with former Team Sky doctors Geert Leinders and Richard Freeman, and the ethical boundaries that his TUE use have thrown up.
Wiggins, who won the Tour de France in 2012, hit the headlines a fortnight ago when the hackers calling themselves Fancy Bears leaked Wiggins’ TUE history. In total six TUEs were issued during Wiggins’ road racing career, however the three intramauscular injections of Triamcinolone acetonide raised eyebrows, with each usage applied before major Grand Tours, one of which - the Tour de France in 2012 – Wiggins won.
Although Wiggins and Team Sky never broke any rules with their application and use of the substance, it raised eyebrows with several respected doctors questioning the timing and nature of the TUE use.
ADVERTISEMENT
In the aftermath of the revelations, Wiggins appeared on a BBC television show but that also created more questions than answers.
However in an exclusive interview with William Fotheringham, Wiggins has talked about his long-standing allergies, and what led him to apply and take several TUEs.
Bradley Wiggins' TUE use
• June 13, 2008: Salbutamol (200ug dosage, inhalation as needed for 12-months)
• December 12, 2008: Salbutamol (250ug dosage, inhalation as needed for 12-months)
• December 16, 2008: Salbutamol (2 puffs dosage, 2 times per day for 12-months), Formoterol (2 puffs dosage, 2 times per day for 12-months), Budesonide (2 inhalations dosage, 2 times per day for 12-months
• June 29, 2011: Triamcinolone acetonide (40mg intramauscular dosage, one time injection)
• June 26, 2012: Triamcinolone acetonide (40mg intramauscular dosage, one time injection)
• April 22, 2013: Triamcinolone acetonide (40mg intramauscular dosage, one time injection)
Ethics versus legality
My Time - updated
The timeline
You can read more at Cyclingnews.com
via Cyclingnews Latest News http://ift.tt/2cRBm2b
No comments:
Post a Comment